J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

The Marketing Association of Pakistan (MAP) has announced its newly elected office bearers and Council members. Muhammad ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

World’s First “Universal” Robotics Software Platform BOW Raises £4 Million Seed to Reduce Cost and Complexity of Programming ...

UnitedHealth reported fourth-quarter results on Thursday that reflected persistent challenges for the health insurance sector.

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...